ViennaLab introduces ss-globulin mutation assay:
This article was originally published in Clinica
A new screening test for nine of the most common Mediterranean ss-globulin mutations has been introduced by ViennaLab (Austria). The test covers over 90% of Mediterranean ss-globin anomalies. The reverse hybridisation-based test takes a day to perform and a single test strip can discriminate between heterozygous-, compound heterozygous- and homozygous-affected individuals. The assay is designed for carrier screening using blood samples, but the company expects it to be able to carry out prenatal diagnosis by chorionic villus sampling if DNA extraction methods suitable for small tissue samples are applied.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.